Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,012 public trials 2,033 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors

NCT03935282

Conditions
Behavior, Breast Diseases, Breast Neoplasm, +42 more
Locations
  • Mercy Hospital Fort Smith Fort Smith, Arkansas, United States
  • Oncology Associates at Mercy Medical Center Cedar Rapids, Iowa, United States
  • Saint Louis Cancer and Breast Institute-Ballwin Ballwin, Missouri, United States
  • Mercy Hospital Springfield Springfield, Missouri, United States
View Trial Details
Completed

Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

NCT02203643

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • IRCCS--CROB --CROB di Rionero in di Rionero in Vulture Rionero in Vulture, Italy
View Trial Details
Completed

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

NCT03213665

Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, +91 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 117 locations
View Trial Details
Completed

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)

NCT04557150

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Peter MacCallum Cancer Center Melbourne, Victoria, Australia
  • UZ Gent Ghent, Belgium
  • Rigshospitalet København Ø, Denmark
  • Odense Universitetshospital Odense C, Denmark
View all 20 locations
View Trial Details
Completed

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

NCT03984097

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Alabama Oncology Birmingham, Alabama, United States
  • Pacific Cancer Care Monterey, California, United States
  • American Oncology Partners of Maryland, PA Bethesda, Maryland, United States
  • Columbia University Medical Center New York, United States
View Trial Details
Completed

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

NCT02625480

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +13 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Children's Hospital of Orange County Orange, California, United States
  • UCSF Benioff Children's Hospital San Francisco, California, United States
  • University of Miami Hospital & Clinics Miami, Florida, United States
View all 30 locations
View Trial Details
Completed

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

NCT04488354

Conditions
Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +47 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of California at San Diego San Diego, California, United States
  • University of Chicago Chicago, Illinois, United States
  • Masonic Cancer Center, University of Minnesota Minneapolis, Minnesota, United States
View Trial Details

Related conditions